Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Statin Combination with Sorafenib in Advanced HCC
NCT03275376Phase 2Terminated
- Sponsor
- Taichung Veterans General Hospital
- Start
- Dec 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atorvastatin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Taichung Veterans General Hospital. Primary endpoint: Overall Survival at 3 years. Started Dec 2017; status: terminated.
02
Drugs
atorvastatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03275376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275376.